Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Co.'s pipeline includes: PRV-031, an anti-CD3 monoclonal antibody for the interception of type 1 diabetes; PRV-101, a coxsackie virus B vaccine to prevent acute infections; PRV-3279, a humanized bispecific scaffold molecule targeting the B-cell surface proteins, for the treatment of systemic lupus erythematosus; PRV-015, a human anti-interleukin 15 monoclonal antibody for the treatment of gluten-free diet non-responding celiac disease; and PRV-6527, an oral small molecule CSF-1R inhibitor.
